These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 29416923)
61. iRGD-liposomes enhance tumor delivery and therapeutic efficacy of antisense oligonucleotide drugs against primary prostate cancer and bone metastasis. Guan J; Guo H; Tang T; Wang Y; Wei Y; Seth P; Li Y; Dehm SM; Ruoslahti E; Pang HB Adv Funct Mater; 2021 Jun; 31(24):. PubMed ID: 34211360 [TBL] [Abstract][Full Text] [Related]
62. iRGD peptide as effective transporter of CuInZnxS2+x quantum dots into human cancer cells. Przysiecka Ł; Michalska M; Nowaczyk G; Peplińska B; Jesionowski T; Schneider R; Jurga S Colloids Surf B Biointerfaces; 2016 Oct; 146():9-18. PubMed ID: 27244046 [TBL] [Abstract][Full Text] [Related]
63. In vivo distribution and antitumor effect of infused immune cells in a gastric cancer model. Du X; Jin R; Ning N; Li L; Wang Q; Liang W; Liu J; Xu Y Oncol Rep; 2012 Nov; 28(5):1743-9. PubMed ID: 22948809 [TBL] [Abstract][Full Text] [Related]
64. Tumor-Specific Peptide, Selected from a Phage Peptide Library, Enhances Antitumor Activity of Lactaptin. Nemudraya AA; Makartsova AA; Fomin AS; Nushtaeva AA; Koval OA; Richter VA; Kuligina EV PLoS One; 2016; 11(8):e0160980. PubMed ID: 27513518 [TBL] [Abstract][Full Text] [Related]
65. Tumor-Penetrating Nanoparticles for Enhanced Anticancer Activity of Combined Photodynamic and Hypoxia-Activated Therapy. Wang Y; Xie Y; Li J; Peng ZH; Sheinin Y; Zhou J; Oupický D ACS Nano; 2017 Feb; 11(2):2227-2238. PubMed ID: 28165223 [TBL] [Abstract][Full Text] [Related]
66. Targeted drug delivery using iRGD peptide for solid cancer treatment. Liu X; Jiang J; Ji Y; Lu J; Chan R; Meng H Mol Syst Des Eng; 2017 Oct; 2(4):370-379. PubMed ID: 30498580 [TBL] [Abstract][Full Text] [Related]
67. An EGFR/CD13 bispecific fusion protein and its enediyne-energized analog show potent antitumor activity. Sheng W; Shang Y; Li L; Zhen Y Anticancer Drugs; 2014 Jan; 25(1):82-91. PubMed ID: 24100279 [TBL] [Abstract][Full Text] [Related]
68. Anticancer activity of Yaghoubi A; Movaqar A; Asgharzadeh F; Derakhshan M; Ghazvini K; Hasanian SM; Avan A; Mostafapour A; Khazaei M; Soleimanpour S Iran J Basic Med Sci; 2023; 26(7):768-776. PubMed ID: 37396945 [TBL] [Abstract][Full Text] [Related]
69. A modified thymosin alpha 1 inhibits the growth of breast cancer both in vitro and in vivo: suppressment of cell proliferation, inducible cell apoptosis and enhancement of targeted anticancer effects. Lao X; Li B; Liu M; Shen C; Yu T; Gao X; Zheng H Apoptosis; 2015 Oct; 20(10):1307-20. PubMed ID: 26283169 [TBL] [Abstract][Full Text] [Related]
70. iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy. Zhang J; Hu J; Chan HF; Skibba M; Liang G; Chen M Nanomedicine; 2016 Jul; 12(5):1303-11. PubMed ID: 26964482 [TBL] [Abstract][Full Text] [Related]
71. Targeting peptide iRGD-conjugated amphiphilic chitosan-co-PLA/DPPE drug delivery system for enhanced tumor therapy. Nie X; Zhang J; Xu Q; Liu X; Li Y; Wu Y; Chen C J Mater Chem B; 2014 Jun; 2(21):3232-3242. PubMed ID: 32261585 [TBL] [Abstract][Full Text] [Related]
72. Ultrasound-Triggered Drug Delivery for Breast Tumor Therapy Through iRGD-Targeted Paclitaxel-Loaded Liposome-Microbubble Complexes. Zhang J; Wang S; Deng Z; Li L; Tan G; Liu X; Zheng H; Yan F J Biomed Nanotechnol; 2018 Aug; 14(8):1384-1395. PubMed ID: 29903054 [TBL] [Abstract][Full Text] [Related]
73. Registered report: Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Kandela I; Chou J; Chow K; Elife; 2015 May; 4():. PubMed ID: 27879198 [TBL] [Abstract][Full Text] [Related]
74. Registered report: Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Kandela I; Chou J; Chow K; ; Elife; 2015 May; 4():. PubMed ID: 25998055 [TBL] [Abstract][Full Text] [Related]
75. Trafficking of T cells into tumors. Slaney CY; Kershaw MH; Darcy PK Cancer Res; 2014 Dec; 74(24):7168-74. PubMed ID: 25477332 [TBL] [Abstract][Full Text] [Related]
76. A bispecific antibody targeting IGF-IR and EGFR has tumor and metastasis suppressive activity in an orthotopic xenograft osteosarcoma mouse model. Gvozdenovic A; Boro A; Born W; Muff R; Fuchs B Am J Cancer Res; 2017; 7(7):1435-1449. PubMed ID: 28744395 [TBL] [Abstract][Full Text] [Related]
77. Selective antibody-mediated targeting of class I MHC to EGFR-expressing tumor cells induces potent antitumor CTL activity in vitro and in vivo. Novak H; Noy R; Oved K; Segal D; Wels WS; Reiter Y Int J Cancer; 2007 Jan; 120(2):329-36. PubMed ID: 17066453 [TBL] [Abstract][Full Text] [Related]
78. Enhancement of radiotherapeutic efficacy for esophageal cancer by paclitaxel-loaded red blood cell membrane nanoparticles modified by the recombinant protein anti-EGFR-iRGD. Ren W; Sha H; Yan J; Wu P; Yang J; Li R; Zhang H; Yu L; Qian H; Liu B J Biomater Appl; 2018 Nov; 33(5):707-724. PubMed ID: 30388386 [TBL] [Abstract][Full Text] [Related]
79. iRGD-conjugated DSPE-PEG2000 nanomicelles for targeted delivery of salinomycin for treatment of both liver cancer cells and cancer stem cells. Mao X; Liu J; Gong Z; Zhang H; Lu Y; Zou H; Yu Y; Chen Y; Sun Z; Li W; Li B; Gao J; Zhong Y Nanomedicine (Lond); 2015; 10(17):2677-95. PubMed ID: 26355733 [TBL] [Abstract][Full Text] [Related]
80. Major effect of transcytosis on nano drug delivery to pancreatic cancer. Liu X; Jiang J; Nel AE; Meng H Mol Cell Oncol; 2017; 4(4):e1335273. PubMed ID: 28868347 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]